Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Metallo-beta-lactamase IMP-type is an enzyme produced by certain Gram-negative bacteria, conferring resistance to a broad spectrum of beta-lactam antibiotics, including carbapenems, penicillins, and cephalosporins. It is a subclass B1 metallo-beta-lactamase, requiring zinc for its catalytic activity, and can efficiently hydrolyze the beta-lactam ring of antibiotics. The IMP-type includes numerous variants, most notably IMP-1, and is encoded by genes that are frequently carried on mobile integron cassettes, facilitating rapid horizontal transfer among bacterial pathogens. These enzymes pose a major clinical threat as they contribute to multidrug-resistant infections and currently lack effective clinical inhibitors, limiting therapeutic options.
Hydrolysis of the beta-lactam ring in antibiotics, rendering them inactive
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Metallo-beta-lactamase IMP-type (IMP-type MBL).